Evidence of sample use among new users of statins: Implications for pharmacoepidemiology

Medical Care

Volumn 52, Issue 9, 2014, Pages 773-780

  Li, Xiaojuan ^a   Stürmer, Til ^a   Alan Brookhart, M ^a  

^a University of North Carolina at Chapel Hill   (United States)

Author keywords

claims databases; epidemiologic methods; exposure misclassification; sample drugs

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ADULT; COHORT ANALYSIS; CONFERENCE PAPER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL DISTRIBUTION; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; CHOLESTEROL, LDL; DATA COLLECTION; DRUG PRESCRIPTIONS; DRUG UTILIZATION; DRUGS, GENERIC; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MARKETING OF HEALTH SERVICES; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; RETROSPECTIVE STUDIES;

EID: 84906088430     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000174     Document Type: Conference Paper

References (41)

1. Crystal S, Akincigil A, Bilder S, et al. Studying prescription drug use and outcomes with Medicaid claims data. Med Care. 2007;45(suppl): S58-S65.
2. Sikka R, Xia F, Aubert R. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11:449-457.
3. Kim SY, Solomon DH. Use of administrative claims data for comparative effectiveness research of rheumatoid arthritis treatments. Arthritis Res Ther. 2011;13:1-29.
4. Soumerai SB, Ross-Degnan D, Avorn J, et al. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med. 1991;325:1072-1077.
5. Nattinger AB, Schapira MM, Warren JL, et al. Methodological issues in the use of administrative claims data to study surveillance after cancer treatment. Med Care. 2002;40(8S):IV69-IV74.
6. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323-337.
7. Choudhry NK, Shrank WH. Four-dollar generics-increased accessibility, impaired quality assurance. N Engl J Med. 2010;363:1885-1887.
8. Lauffenburger JC, Balasubramanian A, Farley JF, et al. Completeness of prescription information in US commercial claims databases. Pharma-coepidemiol Drug Saf. 2013;22:899-906.
9. Kornfield R, Donohue J, Berndt ER, et al. Promotion of prescription drugs to consumers and providers, 2001-2010. PLoS One. 2013;8: e55504.
10. The Kaiser Family Foundation. Kaiser Family Foundation National Survey of Physicians, Toplines. 2006. Available at: http://www.kff.org/kaiserpolls/ upload/7584.pdf. Accessed December 23, 2013.
11. Alexander GC, Zhang J, Basu A. Characteristics of patients receiving pharmaceutical samples and association between sample receipt and out-of-pocket prescription costs. Med Care. 2008;46:394-402.
12. Sufrin CB, Ross JS. Pharmaceutical industry marketing: understanding its impact on women's health. Obstet Gynecol Surv. 2008;63:585-596.
13. Backer EL, Lebsack JA, Van Tonder RJ, et al. The value of pharmaceutical representative visits and medication samples in community-based family practices. J Fam Pract. 2000;49:811-816.
14. Jacobus S, Schneeweiss S, Chan KA. Exposure misclassification as a result of free sample drug utilization in automated claims databases and its effect on a pharcoepidemiology study of selective COX-2 inhibitiors. Pharmacoepidemiol Drug Saf. 2004;13:695-702.
15. Polinski JM, Schneeweiss S, Levin R, et al. Completeness of retail pharmacy claims data: implications for pharmacoepidemiologic studies and pharmacy practice in elderly patients. Clin Ther. 2009;31: 2048-2059.
16. Zhang J, Yun H, Wright N, et al. Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies. Curr Rheumatol Rep. 2011;13:273-282.
17. Van Staa T, Abenhaim L, Leufkens H. A study of the effects of exposure misclassification due to the time-window design in pharma-coepidemiology studies. J Clin Epidemiol. 1994;47:183-189
18. NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
19. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4s). Lancet. 1994;344: 1383-1389
20. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
21. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2013. Doi:10.1161/01.cir.0000437738.63853.7a.
22. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
23. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholester-olemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arte-rioscler Thromb Vasc Biol. 1995;15:678-682.
24. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-Analysis. BMJ. 2003;326:1423-1427.
25. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med. 2004; 164:1427-1436.
26. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152-160.
27. Cutrona SL, Woolhandler S, Lasser KE, et al. Characteristics of recipients of free prescription drug samples: a nationally representative analysis. Am J Public Health. 2008;98:284-289.
28. McLachlan G, Peel D. Finite Mixture Models. New York, NY: John Wiley & Sons Inc; 2000.
29. Benaglia T, Chauveau D, Hunter DR, et al. Mixtools: an R package for analyzing finite mixture models. J Stat Softw. 2009;32:1-29. Available at: http://www.jstatsoft.org/v32/i06/.
30. Fahey MT, Ferrari P, Slimani N, et al. Identifying dietary patterns using a normal mixture model: application to the EPIC study. J Epidemiol Community Health. 2012;66:89-94.
31. McLachlan GJ, Bean RW, Jones LB. A simple implementation of a normal mixture approach to differential gene expression in multiclass microarrays. Bioinformatics. 2006;22:1608-1615.
32. Schlattmann P. Medical Applications of Finite Mixture Models. Berlin, Heidelberg: Springer; 2009.
33. Conway KS, Deb P. Is prenatal care really ineffective? Or, is the "devil" in the distribution? J Health Econ. 2005;24:489-513.
34. Wedel M, Kamakura WA. Market Segmentation-Conceptual and Methodological Foundations. Boston, MA: Kluwer Academic Publishers; 2001.
35. Kaakeh R, Hutton DW, Funk K, et al. Cost-effectiveness of 3 statin sample policies in post-myocardial infarction patients. Am J Pharm Benefits. 2013;5:e36-e45.
36. Gamble JM, McAlister FA, Johnson JA, et al. Quantifying the impact of drug exposure misclassification due to restrictive drug coverage in administrative databases: a simulation cohort study. Value Health. 2012;15:191-197.
37. Greenland S. Confounding and exposure trends in case-crossover and case-time-control designs. Epidemiology. 1996;7:231-239.
38. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the health user effect. Am J Epidemiol. 2007;166:348-354.
39. Brookhart MA, Stürmer T, Glynn RT, et al. Confounding control in healthcare database research: challenges and potential approaches. Med Care. 2010;48(suppl):S114-S120.
40. Platt RW, Schisterman EF, Cole SR. Time-modified confounding. Am J Epidemiol. 2009;170:687-694.
41. Brookhart A. Early experiences with laboratory data in pharmacoepi-demiologic databases. Presented at the 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Barcelona, Spain, August 23, 2012.